Skip to main content

Table 2 Change in HbA1c values at 6 and 12 months after randomization for all 4 analysis groups

From: Efficacy of a pharmacist-managed diabetes clinic in high-risk diabetes patients, a randomized controlled trial - “Pharm-MD”

 

SOC + PMDC

SOC

P-Value

Intent-to-Treat Analysis

 Change in HbA1c at 6 Months

(n = 37) -2.85 (2.69)

(n = 34) -1.32 (1.66)

0.0051

 Change in HbA1c at 12 Months

(n = 30) -2.79 (2.41)

(n = 31) -1.52 (1.92)

0.0259

Intent-to-Treat with LOCF

 Change in HbA1c at 6 Months

(n = 44) -2.46 (2.63)

(n = 42) -0.94 (1.80)

0.0024

 Change in HbA1c at 12 Months

(n = 44) -2.42 (2.43)

(n = 42) -1.39 (2.08)

0.0370

Per Protocol Analysis

 Change in HbA1c at 6 Months

(n = 29) -3.06 (2.91)

(n = 42) -1.47 (1.66)

0.0111

 Change in HbA1c at 12 Months

(n = 23) -2.79 (2.56)

(n = 38) -1.76 (1.98)

0.0816

Per Protocol with LOCF

 Change in HbA1c at 6 Months

(n = 32) -2.87 (2.84)

(n = 54) -1.04 (1.76)

0.0020

 Change in HbA1c at 12 Months

(n = 32) -2.58 (2.58)

(n = 54) -1.53 (2.07)

0.0415

  1. SOC Standard of care, PMDC Pharmacy managed diabetes clinic, HgA1c Hemoglobin A1c, LOCF Last observation carried forward
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us